Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinopharm Medicine To Launch IPO In Hong Kong

This article was originally published in PharmAsia News

Executive Summary

Sinopharm Medicine Holding, a core subsidiary of Sinopharm, will launch its initial public offering in Hong Kong soon, according to sources who disclosed that the firm has obtained approval from the authorities and will hold a public hearing next week. The official listing, targeted for late August or early September, is expected to raise up to RMB 7 billion ($1.02 billion). However, Sinopharm Medicine Holding denied the news, but said that it would likely restructure the pharmaceutical and trade business with another Sinopharm listed subsidiary Accord Pharm after the IPO if it occurs. The move is to boost the company's poor performance in retail drugstore business, which currently only accounts for 3.6 percent of its total revenue. (Click here for more - Chinese Language)

You may also be interested in...



The COVID-19 Effect: Medicare Part B Oncology Drug Claims Down 40% Through April

Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.

NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols

At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.

US FDA Waives Warning Cap Requirement For Neuromuscular Agents As Demand Outranks Safety Worries

COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.

UsernamePublicRestriction

Register

LL1132087

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel